Jibran A Ahmed, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 5 years
- Graduated 2021
Offices
1 location · Mindful Health Solutions A Professional Medical Corporation · 55 clinicians in this group
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Jibran A Ahmed’s office at (415) 964-5137 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
State licence records
2 licences
- Washington ARNP.AP.61172870-NPAdvanced Registered Nurse Practitioner License · since 2021 · expires 2024-07-15ExpiredNo board action on this licenceCheck it with the state
- Washington RN.RN.60865339Registered Nurse License · since 2018 · expires 2024-07-15ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Medicaid work
$102,515 in 2022
Medicaid paid $102,515 for 1,022 billed services this clinician did in 2022, up to 103 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 636 | $67,138 |
| Long return visit (40+ min) | 118 | $18,970 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 91 | $6,256 |
| Nursing assessment / evaluation | 83 | $5,694 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 46 | $3,124 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 48 | $1,333 |
| 2022 | 1,022 | 6 | 103 | $102,515 |
| 2021 | 679 | 5 | 91 | $68,230 |
| 2020 | 54 | 1 | 27 | $0 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 305 | $29,841 |
| Long return visit (40+ min) | 185 | $28,265 |
| Nursing assessment / evaluation | 92 | $6,423 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 83 | $3,701 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 14 | $0 |
2020
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 54 | $0 |
Drugs they prescribed that Part D paid
$2,356
Pharmacies billed $2,356 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 183) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
178 generic and fewer than 11 brand-name prescriptions · $2,356 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Divalproex | 11 | $204 | $19 |
| Venlafaxine Hcl Er | 22 | $196 | $9 |
| Bupropion Xl | 13 | $123 | $9 |
| Hydroxyzine Pamoate | 19 | $104 | $5 |
| Lithium Carbonate | 12 | $81 | $7 |
See all 8 drugs
| Divalproex | 11 | $204 | $19 |
| Venlafaxine Hcl Er | 22 | $196 | $9 |
| Bupropion Xl | 13 | $123 | $9 |
| Hydroxyzine Pamoate | 19 | $104 | $5 |
| Lithium Carbonate | 12 | $81 | $7 |
| Sertraline | 11 | $20 | $2 |
| Alprazolam | 15 | $16 | $1 |
| Escitalopram | 14 | $12 | $1 |
Year by year
| 2024 | 183 | 14 | 0% (0) | None | $2,356 |
| 2023 | 429 | 42 | 0% (0) | 18% | $36,024 |
| 2022 | 1,901 | 85 | 0% (0) | 10% | $426,352 |
| 2021 | 803 | 59 | 0% (0) | 12% | $254,369 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Eliquis | 34 | $10,143 | $298 |
| Potassium Chloride | 11 | $1,347 | $122 |
| Irbesartan | 14 | $423 | $30 |
| Amlodipine Besylate | 20 | $260 | $13 |
| Gabapentin | 13 | $227 | $17 |
| Bupropion Xl | 11 | $194 | $18 |
| Levothyroxine | 12 | $163 | $14 |
| Furosemide | 14 | $120 | $9 |
| Simvastatin | 11 | $119 | $11 |
2022: 42 drugs
| Austedo | 16 | $85,337 | $5,334 |
| Invega Sustenna | 29 | $78,999 | $2,724 |
| Abilify Maintena | 27 | $61,388 | $2,274 |
| Risperdal Consta | 57 | $54,240 | $952 |
| Latuda | 24 | $40,112 | $1,671 |
| Paliperidone Er | 19 | $13,520 | $712 |
| Aripiprazole | 111 | $6,549 | $59 |
| Clozapine | 24 | $6,014 | $251 |
| Fluphenazine | 14 | $4,987 | $356 |
| Divalproex Sodium Er | 39 | $4,153 | $106 |
| Viibryd | 12 | $3,920 | $327 |
| Olanzapine | 182 | $3,886 | $21 |
| Haloperidol | 61 | $3,159 | $52 |
| Atomoxetine | 13 | $2,233 | $172 |
| Prazosin | 46 | $2,170 | $47 |
| Divalproex | 51 | $2,083 | $41 |
| Ziprasidone | 34 | $2,074 | $61 |
| Quetiapine | 76 | $1,921 | $25 |
| Buspirone | 70 | $1,542 | $22 |
| Haloperidol Decanoate | 20 | $1,335 | $67 |
| Duloxetine | 56 | $1,286 | $23 |
| Benztropine Mesylate | 102 | $1,284 | $13 |
| Fluoxetine | 60 | $1,269 | $21 |
| Hydroxyzine | 37 | $1,249 | $34 |
| Risperidone | 72 | $1,215 | $17 |
| Trazodone | 60 | $1,143 | $19 |
| Hydroxyzine Pamoate | 60 | $1,005 | $17 |
| Lamotrigine | 81 | $937 | $12 |
| Gabapentin | 26 | $763 | $29 |
| Sertraline | 57 | $722 | $13 |
| Bupropion Hcl Sr | 36 | $571 | $16 |
| Venlafaxine | 20 | $548 | $27 |
| Propranolol | 24 | $519 | $22 |
| Trihexyphenidyl | 16 | $480 | $30 |
| Venlafaxine Hcl Er | 29 | $378 | $13 |
| Mirtazapine | 24 | $367 | $15 |
| Lithium Carbonate | 34 | $350 | $10 |
| Lithium Carbonate Er | 15 | $306 | $20 |
| Citalopram Hbr | 26 | $173 | $7 |
| Clonidine | 11 | $133 | $12 |
| Paroxetine | 11 | $70 | $6 |
| Clonazepam | 19 | $47 | $2 |
2021: 29 drugs
| Austedo | 11 | $46,403 | $4,218 |
| Latuda | 19 | $42,410 | $2,232 |
| Invega Sustenna | 14 | $42,291 | $3,021 |
| Abilify Maintena | 15 | $34,041 | $2,269 |
| Aripiprazole | 43 | $3,632 | $84 |
| Ziprasidone | 18 | $1,568 | $87 |
| Oxcarbazepine | 13 | $1,528 | $118 |
| Olanzapine | 64 | $1,487 | $23 |
| Haloperidol | 22 | $1,378 | $63 |
| Divalproex Sodium Er | 16 | $1,338 | $84 |
| Divalproex | 26 | $864 | $33 |
| Hydroxyzine Pamoate | 24 | $813 | $34 |
| Quetiapine | 31 | $800 | $26 |
| Prazosin | 13 | $700 | $54 |
| Fluoxetine | 35 | $688 | $20 |
| Duloxetine | 21 | $643 | $31 |
| Buspirone | 31 | $634 | $20 |
| Benztropine Mesylate | 45 | $579 | $13 |
| Risperidone | 36 | $551 | $15 |
| Hydroxyzine | 28 | $503 | $18 |
| Trazodone | 24 | $450 | $19 |
| Gabapentin | 15 | $369 | $25 |
| Sertraline | 21 | $355 | $17 |
| Propranolol | 12 | $337 | $28 |
| Lamotrigine | 20 | $270 | $13 |
| Mirtazapine | 16 | $223 | $14 |
| Lithium Carbonate | 17 | $204 | $12 |
| Bupropion Hcl Sr | 11 | $118 | $11 |
| Citalopram Hbr | 16 | $81 | $5 |
Money from drug and device companies
$813 in 2025
| 2025 | 9 | 30 | None | $813 |
| 2024 | 4 | 4 | None | $116 |
| 2023 | 2 | 3 | None | $79 |
| 2022 | 5 | 7 | None | $283 |
| 2021 | 1 | 2 | None | $66 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Otsuka America Pharmaceutical | Rexulti | $171 | 4 payments
|
| Alkermes | Aristada | $124 | 6 payments
|
| Janssen Pharmaceuticals | Spravato | $112 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $105 | 3 payments
|
| Abbvie | Vraylar | $96 | 5 payments
|
| Supernus Pharmaceuticals | Qelbree | $91 | 4 payments
|
See all 30 published payments
| Alkermes | Meals · 2025-12-09 | Aristada | $24 |
| Abbvie | Meals · 2025-12-01 | Vraylar | $19 |
| Supernus Pharmaceuticals | Meals · 2025-11-10 | None | $21 |
| Alkermes | Meals · 2025-11-03 | Aristada | $23 |
| Janssen Pharmaceuticals | Meals · 2025-10-27 | Spravato | $18 |
| Abbvie | Meals · 2025-10-20 | Vraylar | $20 |
| Supernus Pharmaceuticals | Meals · 2025-10-13 | None | $23 |
| Janssen Scientific Affairs | Meals · 2025-10-06 | Spravato | $34 |
| Abbvie | Meals · 2025-09-25 | Vraylar | $22 |
| Janssen Pharmaceuticals | Meals · 2025-08-18 | Spravato | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-08-14 | Rexulti | $19 |
| Alkermes | Meals · 2025-08-07 | Aristada | $23 |
| Abbvie | Meals · 2025-07-25 | Vraylar | $18 |
| Supernus Pharmaceuticals | Meals · 2025-07-08 | Qelbree | $25 |
| Alkermes | Meals · 2025-06-25 | Aristada | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-17 | Caplyta | $33 |
| Abbvie | Meals · 2025-06-12 | Vraylar | $17 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-15 | Caplyta | $32 |
| Alkermes | Meals · 2025-05-13 | Aristada | $22 |
| Vanda Pharmaceuticals | Meals · 2025-05-06 | Hetlioz | $33 |
| Vanda Pharmaceuticals | Meals · 2025-04-22 | Hetlioz | $39 |
| Alkermes | Meals · 2025-04-15 | Aristada | $14 |
| Otsuka America Pharmaceutical | Meals · 2025-04-03 | Rexulti | $120 |
| Supernus Pharmaceuticals | Meals · 2025-03-06 | None | $23 |
| Janssen Pharmaceuticals | Meals · 2025-02-28 | Spravato | $30 |
| Janssen Pharmaceuticals | Meals · 2025-02-25 | Spravato | $43 |
| Vanda Pharmaceuticals | Meals · 2025-02-20 | Hetlioz | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-02-18 | Rexulti | $11 |
| Otsuka America Pharmaceutical | Meals · 2025-01-24 | Rexulti | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-07 | Trintellix | $15 |
See earlier years (2024, 2023, 2022, 2021)
2024: $116
| Janssen Pharmaceuticals | Spravato | $35 | 1 payment
|
| Abbvie | Vraylar | $34 | 1 payment
|
| Alkermes | Aristada | $25 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $21 | 1 payment
|
2023: $79
| AbbVie | Vraylar | $61 | 2 payments
|
| Lundbeck | Rexulti | $18 | 1 payment
|
2022: $283
| Janssen Pharmaceuticals | Spravato | $199 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $24 | 1 payment
|
| Iti | Caplyta | $23 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $18 | 1 payment
|
| Alkermes | Aristada | $18 | 1 payment
|
2021: $66
| Iti | Caplyta | $66 | 2 payments
|
Professional record
- NPI
- 1992311823
- Licence
- CA 95020754, CA 95281954, WA AP61172870, WA RN60865339Washington ARNP.AP.61172870-NP: ExpiredWashington RN.RN.60865339: Expired
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 4100 Newport Place Dr Ste 730, Newport Beach, CA, 92660
- NPI first listed
- 2020-09-16
- NPI last updated
- 2023-11-20
- NPI record certified
- 2023-11-20
This is when the NPI record was last certified, not a medical board exam.